DS-1103 is under clinical development by Integral Molecular and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DS-1103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DS-1103 overview

DS-1103 is under development for the treatment of solid tumor, breast cancer and non-small cell lung cancer. The drug candidate is developed based on membrane proteins (MPS) discovery platform. It is administered through intravenous route. It acts by targeting SIRPa.

Integral Molecular overview

Integral Molecular is a pharmaceutical company. The company develops and licenses technologies for advancing clinical pipeline of various biotechnology companies. It also offers a pipeline of therapeutic antibodies against membrane protein targets. The company harnesses its membrane protein solutions (MPS) platform for discovering monoclonal antibodies against multipass membrane proteins; lipoparticle technology for immunization and screening of antibodies; and epitope mapping platform for selection of lead candidates and identification of amino-acid resolution epitope. Integral Molecular offers membrane proteome array designing, antibody discovery and engineering, antigen optimization and epitope mapping services. The company also offers SARS-CoV-2 Reporter Virus Particles (RVPs) for testing the presence of neutralizing antibodies in patients and assess the effectiveness of vaccines, and efficacy of drugs. Its prominent partners include Merus NV, Ono Pharmaceutical Co Ltd, National Institute of Allergy and Infectious Diseases and others to develop antibodies. Integral Molecular is headquartered in Philadelphia, Pennsylvania, the US.

For a complete picture of DS-1103’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.